Auro Laboratories [AUROLAB] vs Innova Captab [INNOVACAP] Detailed Stock Comparison
Auro Laboratories
BSE
Loading...
Innova Captab
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Auro Laboratories wins in 4 metrics, Innova Captab wins in 13 metrics, with 0 ties. Innova Captab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Auro Laboratories | Innova Captab | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 145.29 | 37.44 | Innova Captab |
| Price-to-Book Ratio | 3.32 | 5.07 | Auro Laboratories |
| Debt-to-Equity Ratio | 104.76 | 35.24 | Innova Captab |
| PEG Ratio | -1.27 | 7.14 | Auro Laboratories |
| EV/EBITDA | 88.13 | 26.94 | Innova Captab |
| Profit Margin (TTM) | 5.96% | 9.98% | Innova Captab |
| Operating Margin (TTM) | -8.69% | 11.68% | Innova Captab |
| EBITDA Margin (TTM) | N/A | 11.68% | N/A |
| Return on Equity | 4.28% | 13.37% | Innova Captab |
| Return on Assets (TTM) | 1.86% | 8.12% | Innova Captab |
| Free Cash Flow (TTM) | $-180.54M | $-1.09B | Auro Laboratories |
| 1-Year Return | 2.63% | 16.46% | Innova Captab |
| Price-to-Sales Ratio (TTM) | 8.64 | 3.74 | Innova Captab |
| Enterprise Value | $1.86B | $51.37B | Innova Captab |
| EV/Revenue Ratio | 11.30 | 3.95 | Innova Captab |
| Gross Profit Margin (TTM) | 67.54% | 37.21% | Auro Laboratories |
| Revenue per Share (TTM) | $26 | $227 | Innova Captab |
| Earnings per Share (Diluted) | $1.57 | $22.70 | Innova Captab |
| Beta (Stock Volatility) | 0.20 | N/A | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Auro Laboratories vs Innova Captab Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Auro Laboratories | -3.33% | -7.33% | -4.38% | -13.53% | -10.49% | -16.18% |
| Innova Captab | -2.09% | 0.46% | -4.62% | -2.11% | -0.23% | -24.99% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Auro Laboratories | 2.63% | 189.75% | 185.44% | 1,208.61% | 4,390.84% | 3,637.29% |
| Innova Captab | 16.46% | 53.72% | 53.72% | 53.72% | 53.72% | 53.72% |
News Based Sentiment: Auro Laboratories vs Innova Captab
Auro Laboratories
News based Sentiment: NEGATIVE
September proved to be a difficult month for Auro Laboratories, with a significant drop in share price and continued revenue declines overshadowing the long-term optimistic projections. The company's financial struggles are evident, making it a high-risk investment, and the upcoming trading window closure suggests potential significant developments are on the horizon.
Innova Captab
News based Sentiment: POSITIVE
Innova Captab reported impressive revenue and profit growth for both Q1 FY2026 and the full fiscal year 2025-26, supported by a 'Buy' rating from JM Financial. While there were shifts in shareholding, particularly a decrease in FII holdings, the overall narrative points towards a positive trajectory for the company.
Performance & Financial Health Analysis: Auro Laboratories vs Innova Captab
| Metric | AUROLAB | INNOVACAP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.50B | ₹48.64B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 4,177 | 33,824 |
| 90 Day Avg. Volume | 6,853 | 40,665 |
| Last Close | ₹220.50 | ₹832.25 |
| 52 Week Range | ₹170.00 - ₹303.00 | ₹662.00 - ₹1,260.00 |
| % from 52W High | -27.23% | -33.95% |
| All-Time High | ₹307.20 (May 06, 2024) | ₹1,260.00 (Jan 06, 2025) |
| % from All-Time High | -28.22% | -33.95% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.52% | 0.20% |
| Quarterly Earnings Growth | -0.52% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.10% |
| Operating Margin (TTM) | -0.09% | 0.12% |
| Return on Equity (TTM) | 0.04% | 0.13% |
| Debt to Equity (MRQ) | 104.76 | 35.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹68.67 | ₹167.66 |
| Cash per Share (MRQ) | ₹1.02 | ₹11.41 |
| Operating Cash Flow (TTM) | ₹74.16M | ₹282.88M |
| Levered Free Cash Flow (TTM) | ₹18.39M | ₹1.28B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Auro Laboratories vs Innova Captab
| Metric | AUROLAB | INNOVACAP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 145.29 | 37.44 |
| Forward P/E | N/A | 20.01 |
| PEG Ratio | -1.27 | 7.14 |
| Price to Sales (TTM) | 8.64 | 3.74 |
| Price to Book (MRQ) | 3.32 | 5.07 |
| Market Capitalization | ||
| Market Capitalization | ₹1.50B | ₹48.64B |
| Enterprise Value | ₹1.86B | ₹51.37B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.30 | 3.95 |
| Enterprise to EBITDA | 88.13 | 26.94 |
| Risk & Other Metrics | ||
| Beta | 0.20 | N/A |
| Book Value per Share (MRQ) | ₹68.67 | ₹167.66 |
Financial Statements Comparison: Auro Laboratories vs Innova Captab
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AUROLAB | INNOVACAP |
|---|---|---|
| Revenue/Sales | ₹27.74M | ₹3.52B |
| Cost of Goods Sold | ₹9.01M | ₹2.21B |
| Gross Profit | ₹18.74M | ₹1.31B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-2.41M | ₹410.54M |
| EBITDA | ₹4.49M | ₹565.82M |
| Pre-Tax Income | ₹-1.06M | ₹426.77M |
| Income Tax | ₹0 | ₹116.62M |
| Net Income (Profit) | ₹-1.06M | ₹310.15M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AUROLAB | INNOVACAP |
|---|---|---|
| Cash & Equivalents | ₹3,000 | ₹155.19M |
| Total Current Assets | ₹215.14M | ₹7.03B |
| Total Current Liabilities | ₹216.42M | ₹3.53B |
| Long-Term Debt | ₹330.85M | ₹2.45B |
| Total Shareholders Equity | ₹429.68M | ₹9.59B |
| Retained Earnings | ₹359.52M | ₹4.53B |
| Property, Plant & Equipment | ₹16.55M | ₹442.93M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AUROLAB | INNOVACAP |
|---|---|---|
| Operating Cash Flow | N/A | ₹378.60M |
| Capital Expenditures | N/A | ₹-1.21B |
| Free Cash Flow | N/A | ₹-908.56M |
| Debt Repayment | N/A | ₹-7.69M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AUROLAB | INNOVACAP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 4,177 | 33,824 |
| Average Daily Volume (90 Day) | 6,853 | 40,665 |
| Shares Outstanding | 6.23M | 57.22M |
| Float Shares | 2.50M | 15.70M |
| % Held by Insiders | 0.60% | 0.72% |
| % Held by Institutions | 0.00% | 0.19% |
Dividend Analysis & Yield Comparison: Auro Laboratories vs Innova Captab
| Metric | AUROLAB | INNOVACAP |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |